Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia

NCT07498647 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout and Hyperuricemia

Interventions

DRUG: BR2251
DRUG: Febuxostat

Sponsor

BioRay Pharmaceutical Co., Ltd.